Optimizing TRPM4 inhibitors in the MHFP6 chemical space.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Mar 2019
Historique:
received: 24 10 2018
revised: 18 12 2018
accepted: 19 01 2019
pubmed: 2 2 2019
medline: 6 3 2019
entrez: 2 2 2019
Statut: ppublish

Résumé

We recently reported 4-chloro-2-(2-chlorophenoxy)acetamido)benzoic acid (CBA) as the first potent inhibitor of TRPM4, a cation channel implicated in cardiac diseases and prostate cancer. Herein we report a structure-activity relationship (SAR) study of CBA resulting in two new potent analogs. To design and interpret our SAR we used interactive color-coded 3D-maps representing similarities between compounds calculated with MHFP6 (MinHash fingerprint up to six bonds), a new molecular fingerprint outperforming other fingerprints in benchmarking virtual screening studies. We further illustrate the general applicability of our method by visualizing the structural diversity of active compounds from benchmarking sets in relation to decoy molecules and to drugs. MHFP6 chemical space 3D-maps might be generally helpful in designing, interpreting and communicating the results of SAR studies. The modified WebMolCS is accessible at http://gdb.unibe.ch and the code is available at https://github.com/reymond-group/webMolCS for off-line use.

Identifiants

pubmed: 30708257
pii: S0223-5234(19)30060-1
doi: 10.1016/j.ejmech.2019.01.048
pii:
doi:

Substances chimiques

Benzoates 0
TRPM Cation Channels 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

167-177

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Clémence Delalande (C)

Department of Chemistry and Biochemistry, National Center for Competence in Research NCCR TransCure, University of Berne, Freiestrasse 3, 3012, Bern, Switzerland.

Mahendra Awale (M)

Department of Chemistry and Biochemistry, National Center for Competence in Research NCCR TransCure, University of Berne, Freiestrasse 3, 3012, Bern, Switzerland.

Matthias Rubin (M)

Institute of Biochemistry and Molecular Medicine, National Center of Competence in Research NCCR TransCure, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland.

Daniel Probst (D)

Department of Chemistry and Biochemistry, National Center for Competence in Research NCCR TransCure, University of Berne, Freiestrasse 3, 3012, Bern, Switzerland.

Lijo C Ozhathil (LC)

Institute of Biochemistry and Molecular Medicine, National Center of Competence in Research NCCR TransCure, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland.

Jürg Gertsch (J)

Institute of Biochemistry and Molecular Medicine, National Center of Competence in Research NCCR TransCure, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland.

Hugues Abriel (H)

Institute of Biochemistry and Molecular Medicine, National Center of Competence in Research NCCR TransCure, University of Bern, Bühlstrasse 28, 3012, Bern, Switzerland.

Jean-Louis Reymond (JL)

Department of Chemistry and Biochemistry, National Center for Competence in Research NCCR TransCure, University of Berne, Freiestrasse 3, 3012, Bern, Switzerland. Electronic address: jean-louis.reymond@dcb.unibe.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH